ArticleAnnals of translational medicine2021

Efficacy and safety of low-dose everolimus combined with endocrine drugs for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer.

Hui-Qiang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.